Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer

J. Blohmer; M. Gore; S. Kuemmel; RHM Verheijen; R. Kimmig; LFAG Massuger; A. du Bois; W.M Smit; D. Weber; C. Deubelbeiss

Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer

J. Blohmer, M. Gore, S. Kuemmel, RHM Verheijen, R. Kimmig, LFAG Massuger, A. du Bois, W.M Smit, D. Weber, C. Deubelbeiss

Research output: Contribution to conference › Abstract › Other research output

Original language	English
Publication status	Published - 2005
Event	ASCO - Orlando, United States Duration: 13 May 2005 → 17 May 2005

Conference

Conference	ASCO
Country/Territory	United States
City	Orlando
Period	13/05/05 → 17/05/05

Cite this

Blohmer, J., Gore, M., Kuemmel, S., Verheijen, RHM., Kimmig, R., Massuger, LFAG., du Bois, A., Smit, W. M., Weber, D., & Deubelbeiss, C. (2005). Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer. Abstract from ASCO, Orlando, United States.

@conference{835ef583a76d4749833a41b4eedf7bc2,

title = "Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer",

author = "J. Blohmer and M. Gore and S. Kuemmel and RHM Verheijen and R. Kimmig and LFAG Massuger and {du Bois}, A. and W.M Smit and D. Weber and C. Deubelbeiss",

year = "2005",

language = "English",

note = "ASCO ; Conference date: 13-05-2005 Through 17-05-2005",

}

Blohmer, J, Gore, M, Kuemmel, S, Verheijen, RHM, Kimmig, R, Massuger, LFAG, du Bois, A, Smit, WM, Weber, D & Deubelbeiss, C 2005, 'Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer', ASCO, Orlando, United States, 13/05/05 - 17/05/05.

Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer. / Blohmer, J.; Gore, M.; Kuemmel, S. et al.
2005. Abstract from ASCO, Orlando, United States.

Research output: Contribution to conference › Abstract › Other research output

TY - CONF

T1 - Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer

AU - Blohmer, J.

AU - Gore, M.

AU - Kuemmel, S.

AU - Verheijen, RHM

AU - Kimmig, R.

AU - Massuger, LFAG

AU - du Bois, A.

AU - Smit, W.M

AU - Weber, D.

AU - Deubelbeiss, C.

PY - 2005

Y1 - 2005

M3 - Abstract

T2 - ASCO

Y2 - 13 May 2005 through 17 May 2005

ER -

Blohmer J, Gore M, Kuemmel S, Verheijen RHM, Kimmig R, Massuger LFAG et al.. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer. 2005. Abstract from ASCO, Orlando, United States.